| Autor: |
Cereja Pantoja KBC; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém 66073-005, PA, Brazil., Azevedo TCB; Hospital Ophir Loyola, Belém 66063-240, PA, Brazil., Carvalho DC; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém 66073-005, PA, Brazil., Monte N; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém 66073-005, PA, Brazil., Cohen Paes AN; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém 66073-005, PA, Brazil., Barros MCDC; Laboratório de Genética Humana e Médica, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém 66077-830, PA, Brazil., Vinagre LWMS; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém 66073-005, PA, Brazil., Freitas ARS; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém 66073-005, PA, Brazil., Burbano RMR; Hospital Ophir Loyola, Belém 66063-240, PA, Brazil., Assumpção PP; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém 66073-005, PA, Brazil., Santos SEBD; Laboratório de Genética Humana e Médica, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém 66077-830, PA, Brazil., Fernandes MR; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém 66073-005, PA, Brazil., Santos NPCD; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém 66073-005, PA, Brazil. |
| Abstrakt: |
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm derived from the balanced reciprocal translocation of chromosomes 9 and 22 t (9q34 and 22q11), which leads to the formation of the Philadelphia chromosome and fusion of the BCR-ABL genes. The first-line treatment for CML is imatinib, a tyrosine kinase inhibitor that acts on the BCR-ABL protein. However, even though it is a target-specific drug, about 25% of patients do not respond to this treatment. The resistance mechanisms involved in this process have been investigated and studies have shown that germinal alterations can influence this mechanism. The aim of this work was to investigate 32 polymorphisms in 24 genes of carcinogenic pathway to verify the influence of these genetic variants on the response to treatment with imatinib. Our results demonstrated that individuals with the recessive GG genotype for the rs2372536 variant in the ATIC gene are approximately three times more likely to experience treatment failure with imatinib ( p = 0.045, HR = 2.726, 95% CI = 0.9986-7.441), as well as individuals with the TT genotype for the rs10821936 variant in the ARID5B gene, who also have a higher risk for treatment failure with imatinib over time ( p = 0.02, HR = 0.4053, IC 95% = 0.1802-0.911). In conclusion, we show that variants in the ATIC and ARIDB5 gene, never screened in previous studies, could potentially influence the therapeutic response to imatinib in patients treated for CML. |
